罗沙司他联合琥珀酸亚铁治疗血液透析患者肾性贫血的临床疗效

Clinical Effect of Roxastat Combined with Ferrous Succinate in the Treatment of Hemodialysis Patients with Renal Anemia

目的探讨罗沙司他联合琥珀酸亚铁在血液透析(HD)患者肾性贫血(RA)中的效果。方法选取40例HD并RA患者,按随机数字表法分成对照组(20例),观察组(20例)。对照组予以重组人促红素(rh EPO)联合琥珀酸亚铁,观察组予以罗沙司他联合琥珀酸亚铁,用药3个月。对比两组临床疗效、铁代谢与贫血状况、不良反应。结果观察组治疗总有效率高于对照组,观察组治疗后铁蛋白(SF)、血红蛋白(Hb)高于对照组,差异有统计学意义(P<0.05);两组不良反应相当,差异无统计学意义(P>0.05)。结论罗沙司他联合琥珀酸亚铁可改善HD并RA患者铁代谢及贫血状况,增强临床疗效,且无严重不良反应。

Objective This paper aims to investigate the effect of roxastat combined with ferrous succinate on hemodialysis(HD)patients with renal anemia(RA).Methods 40 patients with HD and RA admitted to our hospital from August 2014 to August 2015 were selected and divided into control group(20 cases)and observation group(20 cases)by random number table method.The control group was given recombinant human erythropoietin(rh EPO)combined with ferrous succinate,and the observation group was given roxastat combined with ferrous succinate for 3 months.The two groups’clinical efficacy,iron metabolism,anemia and adverse reactions were compared.Results The total effective rate of the observation group was higher than that of the control group,and the ferritin(SF)and hemoglobin(Hb)of the observation group were higher than those of the control group after treatment,with statistical difference(P<0.05).Adverse reactions were similar between the two groups,and the difference was not statistically significant(P>0.05).Conclusion Roxastat combined with ferrous succinate can improve iron metabolism and anemia status in patients with HD and RA,and enhance clinical effect without serious adverse reactions.